TB remedy price prone to come down as key patent drug by Johnson and Johnson rejected
Express News Service
NEW DELHI: In a serious improvement, the Indian Patents Office on Thursday rejected world pharma main Johnson and Johnson’s (J&J) utility looking for an extension to its patent on anti-Tuberculosis (TB) drug Bedaquiline past July 2023.
The information, which got here on the eve of World TB Day, will assist convey down the remedy price for the illness that impacts the lungs. The improvement will break the monopoly of the pharma main on the important thing anti-Tuberculosis drug.
This will open doorways for Indian producers to fabricate generic medicines at an inexpensive price. The life-saving drug is mixed with different medicines to deal with tuberculosis when the primary line of remedy fails. The judgment was given in a plea filed by two TB survivors, Nandita Venkatesan, a two-time TB survivor, and Phumeza Tisile, one other TB survivor from South Africa.
The patent workplace invoked Section 3 (d) in its judgment because the Indian patent regulation doesn’t permit the evergreening of patents and prevents pharma majors from extending the patent past the stipulated monopoly on the drug. Tweeting the announcement, Venkatesan stated, “We did it! In a landmark verdict, the Indian Patent Office rejected Johnson and Johnson’s patent application to extend the monopoly on key anti-TB drug #Bedaquiline! @ptisile and I – both of us TBsurvivors — had filed pre-grant opposition against the application.”
“Bedaquiline is a key anti-TB drug for people with severe TB that has been shown to improve cure rates and have lesser side effects,” she tweeted. Venkatesan, in an announcement by Médecins Sans Frontières/Doctors Without Borders (MSF), stated, “My fellow TB survivor Phumeza Tisile from South Africa and I filed a patent challenge against J&J in 2019, because we wanted to ensure that the safer, oral and more efficacious drug Bedaquiline was available to all people who need it and to make sure that no one ever has to endure side effects like we did, such as permanent hearing loss.”
A complete of 21.4 lakh tuberculosis (TB) circumstances have been notified in India in 2021 — 18 per cent larger than in 2020 — with over 22 crore folks screened nationwide for early detection and remedy, in line with the WHO’S Global TB report. With 28 per cent of circumstances, India was among the many eight international locations accounting for greater than two-thirds (or 68.3 per cent) of the whole TB sufferers’ rely.
No ever-greening, drug costs set to fall
Indian Patents Office rejects J&J request for for an extension of its patent on anti-TB drug past July 2023
The determination will decrease the fee as it would break the monopoly of the pharma main
The patent workplace in its judgment says the Indian regulation doesn’t permit the evergreening of patents
NEW DELHI: In a serious improvement, the Indian Patents Office on Thursday rejected world pharma main Johnson and Johnson’s (J&J) utility looking for an extension to its patent on anti-Tuberculosis (TB) drug Bedaquiline past July 2023.
The information, which got here on the eve of World TB Day, will assist convey down the remedy price for the illness that impacts the lungs. The improvement will break the monopoly of the pharma main on the important thing anti-Tuberculosis drug.
This will open doorways for Indian producers to fabricate generic medicines at an inexpensive price. The life-saving drug is mixed with different medicines to deal with tuberculosis when the primary line of remedy fails. The judgment was given in a plea filed by two TB survivors, Nandita Venkatesan, a two-time TB survivor, and Phumeza Tisile, one other TB survivor from South Africa.googletag.cmd.push(perform() googletag.show(‘div-gpt-ad-8052921-2’); );
The patent workplace invoked Section 3 (d) in its judgment because the Indian patent regulation doesn’t permit the evergreening of patents and prevents pharma majors from extending the patent past the stipulated monopoly on the drug. Tweeting the announcement, Venkatesan stated, “We did it! In a landmark verdict, the Indian Patent Office rejected Johnson and Johnson’s patent application to extend the monopoly on key anti-TB drug #Bedaquiline! @ptisile and I – both of us TBsurvivors — had filed pre-grant opposition against the application.”
“Bedaquiline is a key anti-TB drug for people with severe TB that has been shown to improve cure rates and have lesser side effects,” she tweeted. Venkatesan, in an announcement by Médecins Sans Frontières/Doctors Without Borders (MSF), stated, “My fellow TB survivor Phumeza Tisile from South Africa and I filed a patent challenge against J&J in 2019, because we wanted to ensure that the safer, oral and more efficacious drug Bedaquiline was available to all people who need it and to make sure that no one ever has to endure side effects like we did, such as permanent hearing loss.”
A complete of 21.4 lakh tuberculosis (TB) circumstances have been notified in India in 2021 — 18 per cent larger than in 2020 — with over 22 crore folks screened nationwide for early detection and remedy, in line with the WHO’S Global TB report. With 28 per cent of circumstances, India was among the many eight international locations accounting for greater than two-thirds (or 68.3 per cent) of the whole TB sufferers’ rely.
No ever-greening, drug costs set to fall
Indian Patents Office rejects J&J request for for an extension of its patent on anti-TB drug past July 2023
The determination will decrease the fee as it would break the monopoly of the pharma main
The patent workplace in its judgment says the Indian regulation doesn’t permit the evergreening of patents
